Format

Send to

Choose Destination
Gynecol Obstet Invest. 2018;83(3):209-219. doi: 10.1159/000485618. Epub 2017 Dec 21.

Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.

Author information

1
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
2
Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China.
3
Department of Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
4
Department of Surgery, The Fourth Hospital of China Medical University, Shenyang, China.

Abstract

BACKGROUND/AIM:

This study aimed to compare neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) with primary debulking surgery (PDS) followed by chemotherapy in patients with advanced ovarian carcinoma International Federation of Gynecology and Obstetrics (FIGO) stages IIIc and IV.

METHODS:

PubMed, the Cochrane Library, and manual searches were applied to discriminate potentially eligible studies published before June 30, 2016.

RESULTS:

A total of 12 comparative studies were finally included; 1,372 patients underwent NAC followed by IDS, and 2,680 patients underwent PDS followed by chemotherapy. For overall pooled estimates, significant between-trial differences were found in the optimal debulking rate, grade 3-5 postoperative adverse reactions, and median overall survival (OS), but no difference was found in the median progression-free survival (PFS). Moreover, a significantly higher incidence was identified in major infections, vascular events, and wound complications for patients in the PDS group.

CONCLUSIONS:

This study suggested that NAC followed by IDS could improve the optimal debulking rate and decrease the postoperative adverse reactions for the current studies, but whether it could improve the OS and PFS compared with PDS followed by chemotherapy in patients with ovarian carcinoma FIGO stages IIIc and IV were still needed to be verified by conducting more randomized controlled trials.

KEYWORDS:

Neoadjuvant chemotherapy; Ovarian carcinoma; Primary surgery

PMID:
29402804
DOI:
10.1159/000485618
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center